atai has administered the first dosage of their VLS-01 synthetic DMT drug in their Phase 1 single-ascending dose (SAD) trial, with topline
Leading psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) has announced the completion of dose administration to 30
Psychedelic biotechnology company Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) announced today confirmation of regulatory approval from the U.K. Medicines and Healthcare
World-class psychedelic biotech firm Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that Former FDA Director Dr. Thomas Laughren has